z-logo
Premium
Amiodarone kinetics after oral doses
Author(s) -
Kannan Ramaswamy,
Nademanee Koonlawee,
Hendrickson Jo Ann,
Rostami Hojat J,
Singh Bramah N
Publication year - 1982
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1982.57
Subject(s) - amiodarone , metabolite , microgram , half life , medicine , pharmacokinetics , active metabolite , oral administration , serum concentration , chemistry , oral dose , pharmacology , endocrinology , atrial fibrillation , biochemistry , in vitro
Amiodarone serum kinetics after single oral doses and after long‐term therapy were investigated in patients with ventricular tachyarrhythmias. When amiodarone was given as a single oral dose (1400 to 1800 mg, n = 6), serum levels of amiodarone and its metabolite, measured by high‐performance liquid chromatography, correlated (r = 0.69, P < 0.01). Peak concentrations (amiodarone, 3 to 14 μg/ml; metabolite, 0.7 μg/ml) were attained in 4.9 ± 1.2 hr. Using computer fits to the data, amiodarone mean elimination rate constant and half‐life (t½e) were 0.128 ± 0.063 hr −1 and 7.2 ± 5.0 hr. In 12 patients given a mean dose of 1327 ± 338 mg/day of amiodarone for 4.1 ± 2.3 wk, mean serum amiodarone level was 3.84 ± 2.92 μg/ml (range 0.92 to 11.99); in three patients simultaneous determination of concentrations of amiodarone and its metabolite revealed that concentration of the latter was about 50% of that of the parent drug during long‐term therapy. In four patients on maintenance therapy (400 to 800 mg/day, serum level 1.08 ± 1.13 μg / ml) drug was discontinued and serum amiodarone levels were determined serially. Serum drug disappearance followed a single exponential function with an elimination rate constant of 0.030 ± 0.012 day −1 and t½e of 29 ± 19 days. Our kinetic data are consistent with the long therapeutic amiodarone t l / 2 noted in the treatment of cardiac arrhythmias. Clinical Pharmacology and Therapeutics (1982) 31, 438–444; doi: 10.1038/clpt.1982.57

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom